Orforglipron, Eli Lilly’s once-daily GLP-1 pill, did not raise the risk of heart attack, stroke or cardiovascular death compared with insulin glargine in 2,749 adults with type 2 diabetes and established heart or kidney disease, according to the ACHIEVE-4 trial published in The Lancet on 30 September. It is the first cardiovascular-outcomes trial of a … Read more
Asked to choose between hypothetical weight-loss drugs, 800 American adults ranked how a drug is taken above how much weight it takes off. In a discrete-choice survey published on 17 September, route of administration was the single most important attribute driving choice, ahead of average weight loss, cardiovascular risk reduction and the share of people … Read more
Eli Lilly posted the full results of ACHIEVE-3 to ClinicalTrials.gov on 15 September 2026, and they are the first detailed head-to-head numbers between the two oral GLP-1 drugs. Over 52 weeks in 1,698 adults with type 2 diabetes, the higher dose of orforglipron lowered blood sugar further than the higher dose of oral semaglutide and … Read more